Literature DB >> 16622479

Potent antibody therapeutics by design.

Paul J Carter1.   

Abstract

Antibodies constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The generation of potent antibody therapeutics, which I review here, is an iterative design process that involves the generation and optimization of antibodies to improve their clinical potential.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16622479     DOI： 10.1038/nri1837

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


  326 in total

1.  2A peptide-based, lentivirus-mediated anti-death receptor 5 chimeric antibody expression prevents tumor growth in nude mice.

Authors:  Meng Li; Yaomin Wu; Yuhe Qiu; Zhenyu Yao; Shilian Liu; Yanxin Liu; Juan Shi; Dexian Zheng
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Elucidation of acid-induced unfolding and aggregation of human immunoglobulin IgG1 and IgG2 Fc.

Authors:  Ramil F Latypov; Sabine Hogan; Hollis Lau; Himanshu Gadgil; Dingjiang Liu
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

Review 3.  Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.

Authors:  Imre Kacskovics; Judit Cervenak; Anna Erdei; Richard A Goldsby; John E Butler
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

4.  Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Hannah Joerissen; Beate Müller-Tiemann; Heiner Apeler; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

5.  Crystal structure of an RNA polymerase ribozyme in complex with an antibody fragment.

Authors:  Joseph A Piccirilli; Yelena Koldobskaya
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-27       Impact factor: 6.237

6.  Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.

Authors:  Arutselvan Natarajan; Frezghi Habte; Sanjiv S Gambhir
Journal:  Bioconjug Chem       Date:  2012-06-11       Impact factor: 4.774

Review 7.  Therapeutic proteins.

Authors:  Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

8.  Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture.

Authors:  James T Heads; Ralph Adams; Lena E D'Hooghe; Matt J T Page; David P Humphreys; Andrew G Popplewell; Alastair D Lawson; Alistair J Henry
Journal:  Protein Sci       Date:  2012-08-09       Impact factor: 6.725

9.  Mutations in the catalytic domain of human matrix metalloproteinase-1 (MMP-1) that allow for regulated activity through the use of Ca2+.

Authors:  Rudolph D Paladini; Ge Wei; Anirban Kundu; Qiping Zhao; Louis H Bookbinder; Gilbert A Keller; H Michael Shepard; Gregory I Frost
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.